Chong Kun Dang retained 10 blockbusters...A total of 67 companies listed 220 blockbusters
Domestic drugmakers ranked top amid strong performance of foreign drugmakers
Last year, Daewoong Pharm and Hanmi Pharm made 12 blockbusters(more than 10 billion won annual sales) each in the outpatient prescription market, jointly leading the sector.
According to the recently released UBIST report, 67 companies produced 220 blockbusters last year.
Compared to 2018, the number of companies with blockbusters increased by 5 and the number of blockbusters increased by 12.
Daewoong Pharm, which held the most blockbusters in 2018, produced 12 blockbusters, including Albis, Urusa, Olmetec and Aricept, which recorded more than 70 billion won in prescription performance last year.
However, Olmetec Plus, which recorded 10.2 billion won in outpatient prescriptions, retreated to 9.8 billion won, and the number of blockbusters decreased from 13 to 12.
Hanmi Pharm, which had 9 blockbusters in 2018 and stayed outside top 5, became co-leader with Daewoong as the number of blockbusters held by Hanmi increased to 12, including new blockbusters Amosartan Plus, Hyalu Mini, RaboneD.
MSD retained 11 blockbusters, the same as in 2018, while CJ HealthCare and AstraZeneca increased by one from 10 to 11.
Chong Kun Dang retained the same ten blockbusters as 2018, followed by Boehringer Ingelheim and Pfizer with 8. The figure is up by one from 2018 for both companies.
Next, Novartis had 7 blockbusters, Takeda and Yuhan had 6, and GSK, Daewon Pharm, Dong-A ST, Astellas, Handok had 5.
SK Chemicals, Bayer, Boryung followed with 4 and JW Pharmaceutical, LG Chem, Daiichi Sankyo, Bukwang Pharm, Samjinpharm, Servier, Janssen, Otsuka followed with 3.
In addition, KyungDong, Kukje Pharma, Novo Nordisk, Green Cross, Daewoong Bio, DHP Korea, Lundbeck, BMS, Sanofi, Santen, Ahn-gook Pharm, Korea United Pharm, Ildong Pharmaceutical, Il-Yang Pharm, Taejoon Pharmaceutical, Ferring, Hanlim also had multiple blockbusters.
Also, Kuhnil Pharm, Korean Drug Co, Gilead, Lilly, Merck, Mundipharma, MyungMoon Pharm, Boryungbio, Sam-A Pharm, Samohpharm, Samil Pharm, Sam Chun Dang Pharm, Celltrion Pharm, Aju Pharm, Abbvie, UCB, YooYoung Pharmaceutical, Yuyu Pharma, PMG Pharm, Korea Prime Pharm, Huons, Huons Medicare, Hutecs had blockbuster.
